开云app官网登录入口网页版-官方正版

#特异性抗体#

88篇内容 | 2208人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1526514, encodeId=a96c152651424, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, objectTitle=J Clin Oncol：新型双特异性抗体ABBV-383在复发/难治性多发性骨髓瘤中初显疗效, objectType=article, longId=737430, objectId=dbc4e37430eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dbc4e37430eb, replyNumber=0, likeNumber=92, createdTime=2022-09-01, rootId=0, userName=hyf032, userId=b8b711724149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dbc4e37430eb, moduleTitle=J Clin Oncol：新型双特异性抗体ABBV-383在复发/难治性多发性骨髓瘤中初显疗效, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=dbc4e37430eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1526513, encodeId=b9eb152651308, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, objectTitle=欧盟批准双特异性抗体Tecvayli（teclistamab）治疗成人复发/难治性多发性骨髓瘤（RRMM）, objectType=article, longId=736911, objectId=1981e36911b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1981e36911b5, replyNumber=0, likeNumber=102, createdTime=2022-08-26, rootId=0, userName=hyf032, userId=b8b711724149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1981e36911b5, moduleTitle=欧盟批准双特异性抗体Tecvayli（teclistamab）治疗成人复发/难治性多发性骨髓瘤（RRMM）, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=1981e36911b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1526512, encodeId=94771526512d6, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, objectTitle=盘点多发性肌炎特异性抗体的研究新进展, objectType=article, longId=734240, objectId=972be342408c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=972be342408c, replyNumber=0, likeNumber=87, createdTime=2022-08-04, rootId=0, userName=hyf032, userId=b8b711724149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=972be342408c, moduleTitle=盘点多发性肌炎特异性抗体的研究新进展, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=972be342408c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1526511, encodeId=dd6f15265115a, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, objectTitle=双特异性抗体中CrossMab技术：过去的10年, objectType=article, longId=727173, objectId=f691e2717303, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f691e2717303, replyNumber=0, likeNumber=82, createdTime=2022-05-19, rootId=0, userName=hyf032, userId=b8b711724149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f691e2717303, moduleTitle=双特异性抗体中CrossMab技术：过去的10年, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=f691e2717303)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1526510, encodeId=9b2d152651054, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, objectTitle=双特异性抗体 epcoritamab 治疗 LBCL 取得积极结果，包括经 CAR-T 细胞疗法治疗失败的患者, objectType=article, longId=724362, objectId=8304e2436281, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8304e2436281, replyNumber=0, likeNumber=81, createdTime=2022-04-17, rootId=0, userName=hyf032, userId=b8b711724149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8304e2436281, moduleTitle=双特异性抗体 epcoritamab 治疗 LBCL 取得积极结果，包括经 CAR-T 细胞疗法治疗失败的患者, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=8304e2436281)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1526509, encodeId=fdba1526509b3, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, objectTitle=AACR 2022：NK细胞及双特异性抗体AFM13复合物持续诱导淋巴瘤缓解, objectType=article, longId=724135, objectId=1e2ae2413509, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e2ae2413509, replyNumber=0, likeNumber=79, createdTime=2022-04-14, rootId=0, userName=hyf032, userId=b8b711724149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e2ae2413509, moduleTitle=AACR 2022：NK细胞及双特异性抗体AFM13复合物持续诱导淋巴瘤缓解, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=1e2ae2413509)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1526508, encodeId=8fa01526508c2, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, objectTitle=“双特异性抗体”受青睐，接力模式为本土创新药出海提速, objectType=article, longId=301538, objectId=0531301538e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0531301538e9, replyNumber=0, likeNumber=114, createdTime=2022-03-25, rootId=0, userName=hyf032, userId=b8b711724149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0531301538e9, moduleTitle=“双特异性抗体”受青睐，接力模式为本土创新药出海提速, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=0531301538e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1526507, encodeId=96ff152650e95, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, objectTitle=Lancet：双特异性抗体faricimab在湿性或新生血管性年龄相关性黄斑变性（AMD）和糖尿病性黄斑水肿（DME）1年的随访结果, objectType=article, longId=294903, objectId=5c2c29490389, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5c2c29490389, replyNumber=0, likeNumber=52, createdTime=2022-01-31, rootId=0, userName=hyf032, userId=b8b711724149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5c2c29490389, moduleTitle=Lancet：双特异性抗体faricimab在湿性或新生血管性年龄相关性黄斑变性（AMD）和糖尿病性黄斑水肿（DME）1年的随访结果, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=5c2c29490389)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1526506, encodeId=ae2f152650646, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, objectTitle=Clin Cancer Res：HER2双特异性抗体KN026单药治疗HER2+转移性乳腺癌的临床试验结果, objectType=article, longId=221530, objectId=eb62221530ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb62221530ea, replyNumber=0, likeNumber=76, createdTime=2021-12-05, rootId=0, userName=hyf032, userId=b8b711724149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb62221530ea, moduleTitle=Clin Cancer Res：HER2双特异性抗体KN026单药治疗HER2+转移性乳腺癌的临床试验结果, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=eb62221530ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1526515, encodeId=57b51526515c1, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, objectTitle=治疗胃食管腺癌达到90.9%疾病控制率，Zymeworks HER2靶向双特异性抗体显“奇效”, objectType=article, longId=259632, objectId=614325963215, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=614325963215, replyNumber=0, likeNumber=77, createdTime=2021-11-07, rootId=0, userName=hyf032, userId=b8b711724149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=614325963215, moduleTitle=治疗胃食管腺癌达到90.9%疾病控制率，Zymeworks HER2靶向双特异性抗体显“奇效”, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=614325963215)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1526505, encodeId=eb171526505bf, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, objectTitle=双特异性抗体——别出“新”裁的下一代免疫治疗, objectType=article, longId=216533, objectId=b436216533d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b436216533d1, replyNumber=0, likeNumber=81, createdTime=2021-09-02, rootId=0, userName=hyf032, userId=b8b711724149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b436216533d1, moduleTitle=双特异性抗体——别出“新”裁的下一代免疫治疗, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=b436216533d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1526504, encodeId=7f38152650436, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, objectTitle=石药集团与美国Flame Biosciences达成超6亿美元合作协议，推进新型双特异性抗体全球化, objectType=article, longId=215927, objectId=011621592e5c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=011621592e5c, replyNumber=0, likeNumber=72, createdTime=2021-08-19, rootId=0, userName=hyf032, userId=b8b711724149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=011621592e5c, moduleTitle=石药集团与美国Flame Biosciences达成超6亿美元合作协议，推进新型双特异性抗体全球化, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=011621592e5c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1526503, encodeId=6226152650353, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, objectTitle=Lancet：双特异性抗体Teclistamab有望成为复发性/难治性多发性骨髓瘤的新疗法！, objectType=article, longId=215591, objectId=5479215591c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5479215591c2, replyNumber=0, likeNumber=0, createdTime=2021-08-13, rootId=0, userName=hyf032, userId=b8b711724149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5479215591c2, moduleTitle=Lancet：双特异性抗体Teclistamab有望成为复发性/难治性多发性骨髓瘤的新疗法！, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=5479215591c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1526502, encodeId=e6aa1526502fb, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, objectTitle=基石药业三特异性抗体CS2006/NM21-1480中国临床试验申请获受理，深度剖析到底有啥优势？, objectType=article, longId=213913, objectId=9af121391339, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9af121391339, replyNumber=0, likeNumber=77, createdTime=2021-07-09, rootId=0, userName=hyf032, userId=b8b711724149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9af121391339, moduleTitle=基石药业三特异性抗体CS2006/NM21-1480中国临床试验申请获受理，深度剖析到底有啥优势？, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=9af121391339)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1526501, encodeId=cc8b15265015e, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, objectTitle=宜明昂科CD47xHER2双特异性抗体获批临床，适应症为HER2表达的晚期实体瘤, objectType=article, longId=213747, objectId=dec0213e4729, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dec0213e4729, replyNumber=0, likeNumber=67, createdTime=2021-07-06, rootId=0, userName=hyf032, userId=b8b711724149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dec0213e4729, moduleTitle=宜明昂科CD47xHER2双特异性抗体获批临床，适应症为HER2表达的晚期实体瘤, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=dec0213e4729)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1526500, encodeId=8f8f1526500b3, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, objectTitle=罗氏PD-1/LAG-3双特异性抗体在中国申报临床，有望用于转移性黑色素瘤、非小细胞肺癌、食管鳞状细胞癌、晚期肝癌多种适应症治疗, objectType=article, longId=213744, objectId=3257213e448e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3257213e448e, replyNumber=0, likeNumber=64, createdTime=2021-07-06, rootId=0, userName=hyf032, userId=b8b711724149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3257213e448e, moduleTitle=罗氏PD-1/LAG-3双特异性抗体在中国申报临床，有望用于转移性黑色素瘤、非小细胞肺癌、食管鳞状细胞癌、晚期肝癌多种适应症治疗, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=3257213e448e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1526499, encodeId=19b015264996e, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, objectTitle=柳叶刀揭示西班牙疫苗混打AZ疫苗与辉瑞疫苗后特异性抗体显著增高, objectType=article, longId=213406, objectId=1ca2213406cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1ca2213406cb, replyNumber=0, likeNumber=69, createdTime=2021-06-30, rootId=0, userName=hyf032, userId=b8b711724149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1ca2213406cb, moduleTitle=柳叶刀揭示西班牙疫苗混打AZ疫苗与辉瑞疫苗后特异性抗体显著增高, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=1ca2213406cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1526498, encodeId=2935152649830, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, objectTitle=JAMA：母乳喂养妇女接种COVID-19疫苗后母乳中有特异性抗体, objectType=article, longId=211539, objectId=d56421153976, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d56421153976, replyNumber=0, likeNumber=0, createdTime=2021-05-21, rootId=0, userName=hyf032, userId=b8b711724149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d56421153976, moduleTitle=JAMA：母乳喂养妇女接种COVID-19疫苗后母乳中有特异性抗体, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=d56421153976)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1526497, encodeId=9f07152649ef4, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, objectTitle=辉瑞暂停BCMA/CD3双抗elranatamab的临床试验，BCMA/CD3双特异性抗体是全球研发热点, objectType=article, longId=210832, objectId=8fed21083275, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8fed21083275, replyNumber=0, likeNumber=80, createdTime=2021-05-06, rootId=0, userName=hyf032, userId=b8b711724149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8fed21083275, moduleTitle=辉瑞暂停BCMA/CD3双抗elranatamab的临床试验，BCMA/CD3双特异性抗体是全球研发热点, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=8fed21083275)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1526496, encodeId=9ec81526496d5, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, objectTitle=J Clin Oncol：新型双特异性抗体Glofitamab用于难治性侵袭性B细胞非霍奇金淋巴瘤的活性, objectType=article, longId=208782, objectId=0413208e8273, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0413208e8273, replyNumber=0, likeNumber=70, createdTime=2021-03-22, rootId=0, userName=hyf032, userId=b8b711724149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0413208e8273, moduleTitle=J Clin Oncol：新型双特异性抗体Glofitamab用于难治性侵袭性B细胞非霍奇金淋巴瘤的活性, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=0413208e8273)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

特异性抗体

2020-05-29

hyf032 (审核中...)

前往app查看评论内容

#特异性抗体#

J Clin Oncol：新型双特异性抗体ABBV-383在复发/难治性多发性骨髓瘤中初显疗效

2022-09-01

hyf032 (审核中...)

前往app查看评论内容

#特异性抗体#

欧盟批准双特异性抗体Tecvayli（teclistamab）治疗成人复发/难治性多发性骨髓瘤（RRMM）

2022-08-26

hyf032 (审核中...)

前往app查看评论内容

#特异性抗体#

盘点多发性肌炎特异性抗体的研究新进展

2022-08-04

hyf032 (审核中...)

前往app查看评论内容

#特异性抗体#

双特异性抗体中CrossMab技术：过去的10年

2022-05-19

hyf032 (审核中...)

前往app查看评论内容

#特异性抗体#

双特异性抗体 epcoritamab 治疗 LBCL 取得积极结果，包括经 CAR-T 细胞疗法治疗失败的患者

2022-04-17

hyf032 (审核中...)

前往app查看评论内容

#特异性抗体#

AACR 2022：NK细胞及双特异性抗体AFM13复合物持续诱导淋巴瘤缓解

2022-04-14

hyf032 (审核中...)

前往app查看评论内容

#特异性抗体#

“双特异性抗体”受青睐，接力模式为本土创新药出海提速

2022-03-25

hyf032 (审核中...)

前往app查看评论内容

#特异性抗体#

Lancet：双特异性抗体faricimab在湿性或新生血管性年龄相关性黄斑变性（AMD）和糖尿病性黄斑水肿（DME）1年的随访结果

2022-01-31

hyf032 (审核中...)

前往app查看评论内容

#特异性抗体#

Clin Cancer Res：HER2双特异性抗体KN026单药治疗HER2+转移性乳腺癌的临床试验结果

2021-12-05

hyf032 (审核中...)

前往app查看评论内容

#特异性抗体#

治疗胃食管腺癌达到90.9%疾病控制率，Zymeworks HER2靶向双特异性抗体显“奇效”

2021-11-07

hyf032 (审核中...)

前往app查看评论内容

#特异性抗体#

双特异性抗体——别出“新”裁的下一代免疫治疗

2021-09-02

hyf032 (审核中...)

前往app查看评论内容

#特异性抗体#

石药集团与美国Flame Biosciences达成超6亿美元合作协议，推进新型双特异性抗体全球化

2021-08-19

hyf032 (审核中...)

前往app查看评论内容

#特异性抗体#

Lancet：双特异性抗体Teclistamab有望成为复发性/难治性多发性骨髓瘤的新疗法！

2021-08-13

hyf032 (审核中...)

前往app查看评论内容

#特异性抗体#

基石药业三特异性抗体CS2006/NM21-1480中国临床试验申请获受理，深度剖析到底有啥优势？

2021-07-09

hyf032 (审核中...)

前往app查看评论内容

#特异性抗体#

宜明昂科CD47xHER2双特异性抗体获批临床，适应症为HER2表达的晚期实体瘤

2021-07-06

hyf032 (审核中...)

前往app查看评论内容

#特异性抗体#

罗氏PD-1/LAG-3双特异性抗体在中国申报临床，有望用于转移性黑色素瘤、非小细胞肺癌、食管鳞状细胞癌、晚期肝癌多种适应症治疗

2021-07-06

hyf032 (审核中...)

前往app查看评论内容

#特异性抗体#

柳叶刀揭示西班牙疫苗混打AZ疫苗与辉瑞疫苗后特异性抗体显著增高

2021-06-30

hyf032 (审核中...)

前往app查看评论内容

#特异性抗体#

JAMA：母乳喂养妇女接种COVID-19疫苗后母乳中有特异性抗体

2021-05-21

hyf032 (审核中...)

前往app查看评论内容

#特异性抗体#

辉瑞暂停BCMA/CD3双抗elranatamab的临床试验，BCMA/CD3双特异性抗体是全球研发热点

2021-05-06

hyf032 (审核中...)

前往app查看评论内容

#特异性抗体#

J Clin Oncol：新型双特异性抗体Glofitamab用于难治性侵袭性B细胞非霍奇金淋巴瘤的活性

2021-03-22

科室
- - 订阅+
  - 更多科室
工具
服务